Last Price
34.28
Today's Change
+26.86 (361.99%)
Day's Change
25.15 - 34.38
Trading Volume
41,955,931
Market Cap
2 Billion
Shares Outstanding
80 Million
Avg Volume
753,445
Avg Price (50 Days)
8.73
Avg Price (200 Days)
12.36
PE Ratio
-15.44
EPS
-2.22
Earnings Announcement
05-Nov-2024
Previous Close
7.42
Open
26.34
Day's Range
25.15 - 34.38
Year Range
6.48 - 34.38
Trading Volume
42,170,180
1 Day Change
361.99%
5 Day Change
363.24%
1 Month Change
326.90%
3 Month Change
342.89%
6 Month Change
138.22%
Ytd Change
95.89%
1 Year Change
374.79%
3 Year Change
19.15%
5 Year Change
266.24%
10 Year Change
121.16%
Max Change
121.16%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.